MannKind to Participate in Upcoming Investor Conferences
MannKind (Nasdaq: MNKD) will provide business updates at two London investor conferences on November 17 and 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MannKind (Nasdaq: MNKD) will provide business updates at two London investor conferences on November 17 and 18, 2026.
CEO Michael Castagna and CFO Chris Prentiss will participate. The UBS Global Biopharma Conference fireside chat is November 17, 11:20–11:50 a.m. GMT; the Jefferies Global Healthcare Conference presentation is November 18, 8:00–8:25 p.m. GMT. Live webcasts and replays for approximately 90 days will be available on MannKind’s Investor Relations website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer, Michael Castagna, and Chief Financial Officer, Chris Prentiss, will provide a business update at two upcoming investor conferences in London.
UBS Global Biopharma Conference
Fireside Chat, Tuesday, November 17 at 11:20-11:50 a.m. GMT
Jefferies Global Healthcare Conference
Presentation, Wednesday, November 18 at 8:00-8:25 p.m. GMT
A live webcast of the presentations will be available on the Events & Presentations section of MannKind’s Investor Relations website. A replay of the webcast will be available on the website for approximately 90 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Contacts: Investor Relations Kate Miranda ir@mnkd.com Media Relations Christie Iacangelo media@mnkd.com